Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy

Document Type : Research Articles


1 Department of Cardiology, University Hospital of Ioannina, Greece.

2 University of Peloponnese, Corinth, Greece.

3 Department of Nursing, TEI of Western Greece, Greece.

4 Department of Dermatology, Medical School of Ioannina, Greece.

5 Department of Ophthalmology, Medical School of Ioannina, Greece.

6 2nd Department of Cardiology University of Ioannina, Greece.

7 Department of Gastroenterology, Medical School of Ioannina, Greece.


Background: Anti-TNFa medications represent the first effective biologic therapy for IBD that has largely
revolutionized treatment. The aim of this study was to quantify the risk of MM and other skin cancers among patients
from Northern Greece area with IBD who take immunosuppressive or biologic anti-TNF medications. Methods:
The current study was conducted during a 3-year period (2014-2016). Clinical history and metabolic data of all patients
were extracted from the IBD database that is kept since 1980. 101 patients with IBD from Northwestern Greece,
were studied. Results: The mean age of enrolled patients was 44.2±15.9 years old ranging from 17 years to 77 years
old. No sun burn was reported from the 44.6% of the patients, 53.5% presented mild reticular veins in the face, and
lack of any elastosis was noticed in 60.4%. The occurrence of two cases with squamous and basal cell carcinoma is
an important finding. The absence of any case with MM should not quiet down but should strengthen our efforts for
further implementation of preventive measures. Conclusions: Furthermore, education of patients to avoid deleterious
sun exposure may help decrease MM incidence.


Main Subjects